全文获取类型
收费全文 | 1482篇 |
免费 | 117篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 106篇 |
妇产科学 | 46篇 |
基础医学 | 145篇 |
口腔科学 | 49篇 |
临床医学 | 105篇 |
内科学 | 323篇 |
皮肤病学 | 25篇 |
神经病学 | 76篇 |
特种医学 | 37篇 |
外国民族医学 | 2篇 |
外科学 | 164篇 |
综合类 | 38篇 |
预防医学 | 242篇 |
眼科学 | 37篇 |
药学 | 128篇 |
中国医学 | 11篇 |
肿瘤学 | 57篇 |
出版年
2023年 | 15篇 |
2022年 | 36篇 |
2021年 | 59篇 |
2020年 | 28篇 |
2019年 | 38篇 |
2018年 | 60篇 |
2017年 | 33篇 |
2016年 | 54篇 |
2015年 | 48篇 |
2014年 | 64篇 |
2013年 | 71篇 |
2012年 | 95篇 |
2011年 | 94篇 |
2010年 | 58篇 |
2009年 | 32篇 |
2008年 | 71篇 |
2007年 | 77篇 |
2006年 | 83篇 |
2005年 | 75篇 |
2004年 | 92篇 |
2003年 | 74篇 |
2002年 | 63篇 |
2001年 | 33篇 |
2000年 | 33篇 |
1999年 | 25篇 |
1998年 | 16篇 |
1997年 | 9篇 |
1996年 | 4篇 |
1995年 | 7篇 |
1994年 | 12篇 |
1993年 | 9篇 |
1992年 | 14篇 |
1991年 | 12篇 |
1990年 | 13篇 |
1989年 | 21篇 |
1988年 | 13篇 |
1987年 | 15篇 |
1986年 | 11篇 |
1985年 | 6篇 |
1984年 | 7篇 |
1983年 | 6篇 |
1979年 | 2篇 |
1975年 | 1篇 |
1974年 | 4篇 |
1972年 | 1篇 |
1971年 | 2篇 |
1969年 | 2篇 |
1968年 | 1篇 |
1967年 | 1篇 |
1966年 | 2篇 |
排序方式: 共有1605条查询结果,搜索用时 15 毫秒
71.
72.
Zahra Eskandariyan Marjan Esfahani Zadeh Kamaleddin Haj Mohammad Ebrahim Tehrani Vida Mashayekhi Farzad Kobarfard 《Archives of pharmacal research》2014,37(3):332-339
A series of 2-(arylmethylthio)-3-phenylquinazolin-4-one derivatives have been synthesized and their antiplatelet aggregation activities were assessed against ADP and arachidonic acid-induced platelet aggregation in human plasma. Among the tested thioethers, derivative 2, 3, 5 and 16 were the most potent compounds with satisfactory IC50 for inhibition of platelet aggregation induced by ADP. Analysis of global physicochemical parameters shows some correlations between activities and molecular volume and also surface area of the studied derivatives. 相似文献
73.
Hossein Poustchi Maryam Darvishian Zahra Mohammadi Amaneh Shayanrad Alireza Delavari Ayad Bahadorimonfared Saeid Eslami Shaghayegh Haghjooy Javanmard Ebrahim Shakiba Mohammad Hossein Somi Amir Emami Nader Saki Ahmad Hormati Alireza Ansari-Moghaddam Majid Saeedi Fatemeh Ghasemi-Kebria Iraj Mohebbi Fariborz Mansour-Ghanaei Reza Malekzadeh 《The Lancet infectious diseases》2021,21(4):473-481
74.
75.
76.
Samaneh Nakhaee Alireza Amirabadizadeh Jeffrey Brent Ebrahim Miri-Moghaddam Mohsen Foadoddini Khadijeh Farrokhfall 《Critical reviews in toxicology》2019,49(8):710-723
AbstractIntroduction: Tramadol is a synthetic opioid which is commonly used around the world to relieve moderate to severe pain. One of the serious possible complications of its use is seizures. The present study aims to investigate and summarize the studies related to tramadol and occurrences of seizures after tramadol use and factors influencing these seizures.Methodology: Our systematic review is compliant with PRISMA guidelines. Two researchers systematically searched PubMed/Medline, Web of Sciences, and Scopus. Cohort, case-control, cross-sectional studies, and clinical trials. The risk of bias was assessed using the Newcastle–Ottawa Scale After article quality assessment, a fixed or random model, as appropriate, was used to pool the results in a meta-analysis. Heterogeneity between the studies was assessed with using I-square and Q-test. Forest plots demonstrating the point and pooled estimates were drawn.Results: A total of 51 articles with total sample size of 101 770 patients were included. The results showed that seizure event rate in the subgroups of tramadol poisoning, therapeutic dosage of tramadol, and tramadol abusers was 38% (95% CI: 27–49%), 3% (95% CI: 2–3%), 37% (95% CI: 12–62%), respectively. Tramadol dose was significantly higher in the patients with seizures than those without (mean differences: 0.82, CI 95%: 0.17–1.46). The odds for occurrence of seizures were significantly associated with male gender (pooled OR: 2.24, CI 95%: 1.80–2.77). Naloxone administration was not associated to the occurrence of seizures (pooled OR: 0.47, 95% CI: 0.15–1.49).Conclusions: Our results demonstrate that the occurrence of seizures in patients exposed to tramadol are dose-dependent and related to male gender, but not related to naloxone administration. Given that, most of the evidence derives from studies utilizing a cross-sectional design, the association of tramadol with seizures should not be considered to be definitively established 相似文献
77.
Majid Naderi Tahereh Zarei Sezaneh Haghpanah Peyman Eshghi Ebrahim Miri-Moghaddam Mehran Karimi 《Annals of hematology》2014,93(4):693-697
Intracranial hemorrhage (ICH) is one of the most severe and life-threatening manifestations occurring in the patients with factor XIII (F XIII) deficiency. The aim of this study was to describe the ICH pattern in the patients suffering from F XIII deficiency. In this case series, we investigated 38 patients with severe F XIII deficiency in south of Iran from January to May 2012. ICH pattern, neurologic complications, efficacy of treatment, and incidence of recurrence were reported. The site of ICH was intraparenchymal in 35 patients (92.1 %), subdural in 2 patients (5.2 %), and epidural hemorrhage in 1 patient (2.6 %). Besides, neurologic complications occurred in 21 patients (55.2 %), including locomotor disability in 8, psychological impairment in 7, mental disorders in 5, speech impairment in 4, and visual impairment in 2. Prophylaxis was started with a dose of 10 IU/kg Fibrogammin every 4–6 weeks for all the patients, except for one. All the patients on prophylaxis showed good response without any episodes of recurrence, except for one. The most frequent site of ICH in our patients was intraparenchymal. It seems that long-term prophylactic treatment with a dose of 10 IU/kg Fibrogammin could be effective in the prevention of CNS bleeding in the patients with F XIII deficiency. Moreover, all the patients with severe F XIII deficiency even without severe bleeding symptoms are recommended to undergo prophylactic treatment. 相似文献
78.
The influence of rituximab therapy on prognosis and hepatic toxicity (HT) in patients with hepatitis C virus (HCV)-positive diffuse large B-cell lymphoma (DLBCL) is unclear. Thus, we assessed HT and clinical outcome in patients with DLBCL and HCV infection who received rituximab-containing immunochemotherapy. We carried out a prospective analysis on a total of 280 HCV-positive patients with DLBCL, 200 of whom received chemotherapy plus rituximab (R-CHT), 80 received chemotherapy (CHT)-only. Survival outcomes and HT were compared according to rituximab administration. The median follow-up was 41 months. Addition of rituximab did not significantly affect prognosis (median progression-free survival, 40 vs 35 months, P?=?0.26; median overall survival, 51 vs 43 months P?=?0.09). Of 200 patients who received rituximab, 53 (26.5 %) had severe HT (grade 3–4), compared with 11 of 80 (13.75 %) patients who received rituximab-free regimens (P?=?0.033). Among patients treated with rituximab, 50 patients (25 %) did not complete planned course of therapy, 14 patients because of hepatic toxicity and 36 patients because of progressive disease. Pretreatment liver function impairment was predictive of severe HT. These results raise concerns regarding the routine use of rituximab with chemotherapy in individuals with HCV-positive DLBCL. However, more studies are warranted before a definitive conclusion can be made. 相似文献
79.
80.